Income Statement (TTM)
Sagimet Biosciences Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
|
|---|---|---|---|---|---|
| Revenue | 2 | 2 | 2 | 2 | 0 |
| Change (%) | 0.00 | 0.00 | 0.00 | -100.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cost Of Sales | |||||
| Change (%) | |||||
| % of Revenue | |||||
| Gross Operating Profit | 2 | 2 | 2 | 2 | 0 |
| Change (%) | 0.00 | 0.00 | 0.00 | -100.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | |
| SG&A | 11 | 13 | 14 | 16 | 16 |
| Change (%) | 21.22 | 9.47 | 13.35 | -1.52 | |
| % of Revenue | 534.70 | 648.15 | 709.55 | 804.30 | |
| R&D | 20 | 20 | 21 | 22 | 30 |
| Change (%) | -0.96 | 3.92 | 7.97 | 34.68 | |
| % of Revenue | 998.40 | 988.85 | 1,027.60 | 1,109.45 | |
| OpEx | 31 | 33 | 35 | 38 | 46 |
| Change (%) | 6.78 | 6.12 | 10.17 | 19.46 | |
| % of Revenue | 1,533.10 | 1,637.00 | 1,737.15 | 1,913.75 | |
| Operating Income | -29 | -31 | -33 | -36 | -46 |
| Change (%) | 7.25 | 6.52 | 10.79 | 26.05 | |
| % of Revenue | -1,433.10 | -1,537.00 | -1,637.15 | -1,813.75 | |
| Interest Expense | |||||
| Change (%) | |||||
| % of Revenue | |||||
| Net Income | -27 | -28 | -28 | -29 | -38 |
| Change (%) | 3.55 | 0.15 | 4.77 | 28.26 | |
| % of Revenue | -1,346.00 | -1,393.80 | -1,395.90 | -1,462.55 | |
Source: Capital IQ
